ABSTRACT
Objective To explore the compound azintamide + mosapride application regimen in elderly patients with gastrointestinal diseases and associated dyspepsia in the treatment. Methods 116 cases of elderly patients with gastrointestinal disease associated dyspepsia patients treated in our hospital from April 2016 to April 2017 were randomly divided into observation group and control group, with 58 cases in each group. The observation group was treated with azintamide + mosapride,the control group was treated with mosapride,the two groups were treated for 28 d .The total score of dyspeptic symptoms before and after treatment in two groups was recorded, and the clinical symptoms were evaluated according to the remission rate of symptom scores. The incidence of adverse reactions in the two groups was calculated and compared between the two groups. Results There was no significant difference in total scores of dyspepsia symptoms between two groups before treatment. The total score of the two groups of dyspepsia symptoms decreased in different degrees after the end of the effective course,the observation group was significantly better than the control group (P<0.05). The effective rate of the observation group was 87.9%, which was significantly higher than that of the control group (60.3%) (P<0.05). Conclusion Compound azintamide combined with Mosapride is effective in the treatment of gastrointestinal diseases associated dyspepsia in elderly patients, combination therapy significantly improved in patients with dyspeptic symptoms, improve the quality of life of patients, clinical application of feedback is good, safe and reliable.
ABSTRACT
Objective To analyze the effect of Compound Azintamide Enteric-coated Tablets combined with laparoscopic cholecystectomy on patients with gallstone and cholecystitis. Methods 72 cases of cholelithiasis and cholecystitis were randomly divided into experimental group and control group, each had 36 cases. Two groups of patients were treated with Compound Azintamide Enteric-coated Tablets, and on this basis, the experimental group received laparoscopic treatment, while the control group was treated with traditional laparotomy. After treatment, the differences between the two groups in general situation, the efficacy and the quality of life were compared. Results The bleeding volume, operation time and treatment in experimental group patients after hospitalization were lower than patients in the control group (P<0.05), the curative effect and quality of life in experimental group were better than patients of control group, the difference were statistically significant (P<0.05). Conclusion Compound Azintamide Enteric-coated Tablets combined laparoscopic surgery on gallstone and cholecystitis has better efficacy and better quality of life.
ABSTRACT
Objective To analyze the effect of Compound Azintamide Enteric-coated Tablets combined with laparoscopic cholecystectomy on patients with gallstone and cholecystitis. Methods 72 cases of cholelithiasis and cholecystitis were randomly divided into experimental group and control group, each had 36 cases. Two groups of patients were treated with Compound Azintamide Enteric-coated Tablets, and on this basis, the experimental group received laparoscopic treatment, while the control group was treated with traditional laparotomy. After treatment, the differences between the two groups in general situation, the efficacy and the quality of life were compared. Results The bleeding volume, operation time and treatment in experimental group patients after hospitalization were lower than patients in the control group (P<0.05), the curative effect and quality of life in experimental group were better than patients of control group, the difference were statistically significant (P<0.05). Conclusion Compound Azintamide Enteric-coated Tablets combined laparoscopic surgery on gallstone and cholecystitis has better efficacy and better quality of life.
ABSTRACT
Objective To explore the efficacy and safety of compound azintamide enteric‐coated tablets in the treatment of patients with dyspepsia after gastrointestinal surgery .Methods Multicenter , randomized ,double blind ,placebo‐controlled ,parallel controlled method w as applied .From January 2011 to January 2013 , of 240 patients with dyspepsia after gastrointestinal surgery from 12 hospitals in Shanghai were enrolled and divided into medicine treatment group (n= 120) and placebo control group (n= 120 ) ,received compound azintamide enteric‐coated tablets or placebo , respectively . Compound azintamide enteric‐coated tablet (100 mg) or placebo was oral taken each time ,three times per day for four weeks .Total and respective score of dyspeptic symptoms (abdominal distension ,loss of appetite ,early satiety ,belching ,nausea ,abdominal pain or abdominal discomfort) were evaluated prior to study and on the 1st , 2nd , 3rd and 4th week after treatment . On the 4th week after treatment ,the efficacy of the improvement of dyspeptic symptoms was compared between the two groups ,and the safety was also evaluated .The score of the quality‐of‐life was compared between the two groups prior to study and on the 4thweek after treatment .The t‐test was performed for comparison between measurement data ,Chi‐square test was used for count data ,and rank sum test was used for rank data .Results At one week after treatment ,the scores of abdominal distension (4 .61 ± 0 .98 ) ,early satiety (2 .87 ± 0 .64 ) ,belching (3 .03 ± 0 .58) ,abdominal pain or abdominal discomfort (3 .13 ± 0 .79) and total score (18 .32 ± 3 .44) of patients in medicine treatment group were significantly lower than those of placebo control group (8 .83 ± 1 .28、4 .28 ± 0 .61、4 .87 ± 1 .07、5 .46 ± 0 .87、29 .63 ± 5 .50) ,and the differences were statistically significant (t=28 .524、17 .400、16 .453、21 .619 and 18 .983 ,all P 0 .05) .At 2nd ,3rd and 4th week after treatment ,respective score of dyspeptic symptoms and total score of medicine treatment group (2nd week:2.57±1.28,1.87±1.17,1.55±1.27,1.55±1.08,1.09±0.82,1.98±1.02,10.53±4.54,3rdweek:1 .42 ± 0 .60 ,1 .11 ± 0 .45 ,0 .94 ± 0 .37 ,0 .94 ± 0 .41 ,0 .79 ± 0 .31 ,1 .42 ± 0 .55 ,6 .52 ± 2 .41 ,4th w eek:1.13±0.51,0.46±0.12,0.58±0.13,0.38±0.16,0.30±0.07,0.81±0.33,3.65±1.06)wereall significantly lower than those of placebo control group (2nd week:8 .50 ± 2 .61 ,3 .78 ± 2 .01 ,4 .08 ± 2 .14 , 4.73±2.64,2.27±2.13,4.91±2.24,28.25±8.86,3rdweek:7.92±2.51,3.68±1.76,4.08±1.86, 4.71±1.77,2.14±0.83,5.01±1.31,27.54±8.09,4th week:7.63±2.37,3.67±1.63,3.92±2.08, 4 .66 ± 2 .95 ,2 .14 ± 1 .65 ,4 .67 ± 2 .34 ,and 26 .68 ± 7 .45) ,and the differences were statistically significant (all t=0 .000 ,all P<0 .01) .At 4th week after treatment ,the total efficacy of total score improvement of dyspepsia symptoms in medicine treatment group was 86 .21% (100/116) ,which was significantly better than that of placebo control group (39 .16% (47/120)) ,and the difference was statistically significant (Z=9 .464 ,P<0 .01) .The total score of quality of life in medicine treatment group was significantly lower than that of placebo control group (12 .24 ± 4 .30 and 22 .13 ± 6 .18) ,and the difference was statistically significant (t=14 .225 , P< 0 .01 ) .No adverse events was observed in both groups during treatment period . Conclusion Compound azintamide enteric‐coated tablets may effectively improve dyspeptic symptoms and quality of life in patients with dyspepsia after gastrointestinal surgery ,and with good safety .
ABSTRACT
Objective To evaluate the efficacy and safety of compound azintamide enteric-coated tablet in the treatment of patients with post-cholecystectomy dyspepsia.Methods A multicentre,randomized,double-blinded,placebo-controlled trail was conducted.A total of 120 patients with post-cholecystectomy dyspepsia were divided into azintamide group (n=60) and placebo group (n＝60),taking compound azintamide enteric-coated tablet or placebo 100 mg each time,three times per day for 28 days.The score of each dyspeptic symptom (abdominal distension,loss of appetite,early satiety,belching,nausea,abdominal pain or abdominal discomfort) and total score of dyspepsia were evaluated prior to study and on the 7th,14th,21st and 28th day after treatment.The efficacy of the improvement of dyspeptic symptoms was compared between the two groups on the 28th day after treatment and the safety was evaluated.The score of the quality-of-life was compared between the two groups prior to study and on the 28th day after treatment.The t-test or chi-square test was performed for statistical analysis.Results The scores of abdominal distension,belching,nausea,abdominal pain or abdominal discomfort and the total score of azintamide group on the 7th day after treatment (5.7±3.1,3.5±2.1,0.3±0.1,3.3±1.7 and 17.9±9.6) were significantly lower than those prior to study (8.9±5.3,5.3±2.5,0.9±0.4,4.5±3.7,24.3±14.5;t=3.758,3.976,10.494,2.125 and 2.654,allP＜0.05).On the14th,21st and28thday after treatment in azintamide group,the score of each dyspeptic symptom and the total score were lower than those prior to study.The symptom of abdominal distension significantly improved on the 7th,14th,21st and 28th day after treatment in placebo group,and the score of early satiety and total score of dyspepsia were significantly lower on the 28th day after treatment compared with those before treatment.In azintamide group,the total efficacy rate was 66.7％ (40/60),which was higher than that of placebo group (38.3％,23/60) and the difference was statistically significant (x2 =9.653,P ＜ 0.01).On the 28th day after treatment,SF-NDI of azintamide group was 4.4±3.4,which was significantly lower than that of placebo group (9.6±6.0) and the difference was statistically significant (t=5.450,P＜0.01).In azintamide group there was one patient with rash on the 7th day after treatment,and in placebo group there was one patient with headache on the 14th day after treatment.The symptoms disappeared seven days after medicine withdrawal.Conclusion Compound azintamide enteric-coated tablet effectively improves dyspeptic symptoms and quality of life in patients with post-cholecysteetomy dyspepsia and has good safety.
ABSTRACT
Objective To study the impact of symptom score ,gastric emptying test and gastric accommodation of compound az-intamide(CA) combined with mosapride(MSP) drugs in patients with functional dyspepsia(FD) .Methods From February 2012 to March 2013 ,112 cases of hospital patients with FD were divided into the observation group (56 cases) and the control group (56 cases) .The control group was given MSP for treatment ,while the observation group was given MSP and CA .The curative effect , symptom scores and gastric accommodation ,as well as gastric emptying test results condition before and after treatment of two groups were Compared .Results The effective rate and the total effective rate of observation group were 51 .79% ,80 .36% ,which were significantly higher than the control group(32 .14% ,51 .79% )(P<0 .05) ;the improvement rate of the observation group was 8 .93% ,which was significantly lower than the control group 25 .00% (P<0 .05) .After treatment ,the observation group′s symp-tom score was (8 .7 ± 6 .3)points ,which was significantly lower than before treatment (22 .4 ± 7 .9)points ,and the control group af-ter treatment (12 .7 ± 3 .6) points ;the maximum amount of drinking water was (387 .1 ± 105 .8)mL ,which was significantly higher than the pre-treatment of (320 .8 ± 90 .9)mL ,and the control group after treatment of (351 .3 ± 77 .7)mL ;After treatment ,2 h full gastric emptying rate was 66 .07% (37/56) ,5 h full gastric emptying rate was 94 .64% (53/56) ,which were significantly higher than before treatment of 10 .71% (6/56) ,23 .21% (13/56) ,and the control group after treatment of 44 .64% (25/56) ,73 .21% (41/56) ,the differences were statistically significant (P<0 .05) .Conclusion CA combined MSP treat FD can significantly improve pa-tient symptoms ,promote gastric emptying ,and increase patients′gastric accommodation .The effect is significant and is worthy of recommendation .
ABSTRACT
Objective To investigate the efficacy and safety of compound azintamide on dyspepsia symptoms. Methods One hundred and eighty dyspepsia patients were divided into two groups according to dyspepsia symptom related with gastrointestinal disease ( group A) or biliary system disease (group B),whose dyspepsia symptom were not improved by the Domperidone 10 mg tid for 2 weeks. Two tablets of compound azintamide were administered orally following a meal, tid for 2 weeks. The changes of symptoms score of upper abdominal distention, upper abdominal pain or discomfort anorexia and effective rate as well as adverse events were recorded. Results Compound azintamide greatly improved the symptoms of upper abdominal distention, upper abdominal pain or discomfort and anorexia. All symptoms scores were significantly decreased after 2 weeks of compound azintamide (P < 0.01). The effective rate of each symptom and total symptoms score were more than 84.9% and 92.5%. One patient reported mild rash at the fourteenth days, which disappeared 3 days later. Conclusion Compound azintamide showed effective and safety in treatment of patient with dyspepsia symptoms when Domperidone therapy is not satisfactory.
ABSTRACT
OBJECTIVE:To investigate the efficacy of compound azintamide enteric-coated tablet plus mosapride citrate dispersible tablet for abdominal distention in patients with functional dyspepsia(FD).METHODS:A total of 80 patients with the chief complaint of abdominal distention were randomized to treatment group(Group A,n=40) to be treated with mosapride citrate dispersed tablets plus compound azintamide enteric-coated tablet,or control group in which the patients were treated bu mosapride citrate dispersed tablets(Group B,n=20) or compound azintamide enteric-coated tablets(Group C,n=20).Comp-ound azintamide enteric-coated tablets were administered orally tid(2 tablets) immediately after meal while the mosapride citrate dispersed tablets(5mg) were administered orally tid 30min before meal for 2 weeks.The main outcome measures were changes of symptom scores of abdominal distension,the total effective rates in improvement of abdominal distension,and drug side effects before and after treatment.RESULTS:After 1-week and 2-week treatment,the average index scores of abdominal distention in the treatment group(Group A) were significantly lower than in the control groups(Group B and Group C) (P
ABSTRACT
OBJECTIVE: To assess the efficacy and safety of compound azintamide and trimebutine maleate in the treatment of functional dyspepsia (FD) in elderly patients. METHODS: 48 elderly patients with FD up to Rome Ⅲ were randomly divided into two groups. Treatment group were given 200 mg trimebutine maleate tid at 15 min before meal and 2 pieces of compound azintamide tid after meal for 4 weeks (n=23). Control group were given 200 mg trimebutine maleate tid for 4 weeks (n=25). Questionnaire survey was applied to detect the index of dyspeptic symptoms and drug toxity before and after treatment. RESULTS: The patients with FD in two groups were matched well in respect of age, sex and index of dyspeptic symptoms. Routine therapy was achieved and adverse reaction wasn’t found. Curative efficacy and symptom score in treatment group were significantly better than in control group after 4 weeks of treatment, such as poor appetite, abdominal distension, early satiety, belching , except upper abdominal pain and burning sensation (P
ABSTRACT
Objective To investigate the effect of compound azintamide enteric-coated tablet on abdominal fullness in patients with functional dyspepsia, chronic cholecystitis with gallbladder stones, or liver cirrhosis. Methods Twenty patients with functional dyspepsia, 20 with chronic cholecystitis and gallbladder stones, and 20 with liver cirrhosis were enrolled in the study. Compound azintamide enteric-coated tablets were given 2 tablets 3 times daily for 4 weeks. The changes of symptom scores of abdominal fullness were investigated after the treatment. Water loading tests were carried out in patients with functional dyspepsia and chronic cholecystitis with gallbladder stones before and after the medication. Results Compound azintamide enteric-coated tablets greatly improved the symptom of abdominal fullness in each group of patients. Symptom scores were significantly decreased in 2 and 4 weeks (P